Gossypium herbaceam extracts inhibited NF-kappaB activation to attenuate spatial memory impairment and hippocampal neurodegeneration induced by amyloid-beta in rats.
Amyloid-beta (Abeta) is considered to be responsible for the pathogenesis of Alzheimer's disease. In the present study, the protective effect of Gossypium herbaceam extracts (GHE) on learning and memory impairment induced by Abeta were examined in vivo using Morris water maze and step through task. Furthermore, the antioxidant activity and neuroprotective effect of GHE was investigated with methods of histochemistry and biochemistry. These data showed that oral administration with GHE at the doses of 35, 70 and 140 mg/kg exerted an improved effect on the learning and memory impairment in rats induced by intracerebroventricular (i.c.v.) injection of 10 microg of Abeta(25-35). Subsequently, the GHE afforded a beneficial action on promotion on the activity of glutathione peroxidase and catalase, as well as inhibition on the NF-kappaB activation in the hippocampus followed by the presence of Abeta(25-35). Meanwhile, the number of degenerating neurons with an apoptotic feature was dramatically decreased in hippocampus after treatment with GHE, implicating that its antioxidant stress and inhibition of NF-kappaB activation could be involved in the mechanism underlying neuroprotection of GHE against Abeta-induced cell death. These findings suggested that GHE might be a potential agent for treatment of Alzheimer's disease.
Ji
Chao
C
School of Basic Medicine, Peking Union Medical College & Institute of Basic Medical Science, Chinese Academy of Medical Sciences, Beijing, China.
Aisa
Haji Akber
HA
Yang
Nan
N
Li
Qing
Q
Wang
Tao
T
Zhang
Ling
L
Qu
Kai
K
Zhu
Hai-Bo
HB
Zuo
Ping-Ping
PP
D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003368:Gossypium; D006624:Hippocampus / Q000378:metabolism* / Q000473:pathology*; D007150:Immunohistochemistry; D008297:Male; D018782:Maze Learning; D008569:Memory Disorders / Q000378:metabolism* / Q000517:prevention & control*; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D009410:Nerve Degeneration / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D008517:Phytotherapy; D010936:Plant Extracts; D051381:Rats; D017207:Rats, Sprague-Dawley; D013028:Space Perception
D016564:Amyloid beta-Protein Precursor; D016328:NF-kappa B; D010936:Plant Extracts